APO RESEARCH · REPORT
Hepatitis B Vaccines
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
Product & engineering
Understand the product.
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
Selected research
Market Structure
Global Hepatitis B Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.
The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.
Read the full market overview
Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 30%.
Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report provides an overview of the global Hepatitis B Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hepatitis B Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hepatitis B Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis B Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
Hepatitis B Vaccines Segment by Company
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
Hepatitis B Vaccines Segment by Type
Yeast Derived
CHO Derived
Hepatitis B Vaccines Segment by Application
Children
Adult
Hepatitis B Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hepatitis B Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatitis B Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hepatitis B Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Yeast Derived
- CHO Derived
Applications
- Children
- Adult
Companies covered
- GSK
- NCPC
- Merck
- Bio Kangtai
- Dynavax
- Hissen
- KM Biologics
- LG Life Sciences
- Serum Institute
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hepatitis B Vaccines Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hepatitis B Vaccines Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hepatitis B Vaccines Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hepatitis B Vaccines Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hepatitis B Vaccines Market Dynamics
- 2.1 Hepatitis B Vaccines Industry Trends
- 2.2 Hepatitis B Vaccines Industry Drivers
- 2.3 Hepatitis B Vaccines Industry Opportunities and Challenges
- 2.4 Hepatitis B Vaccines Industry Restraints
3 Hepatitis B Vaccines Market by Manufacturers
- 3.1 Global Hepatitis B Vaccines Revenue by Manufacturers (2021-2026)
- 3.2 Global Hepatitis B Vaccines Sales by Manufacturers (2021-2026)
- 3.3 Global Hepatitis B Vaccines Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hepatitis B Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hepatitis B Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hepatitis B Vaccines Manufacturers, Product Type & Application
- 3.7 Global Hepatitis B Vaccines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hepatitis B Vaccines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hepatitis B Vaccines Players Market Share by Revenue in 2025
- 3.8.3 2025 Hepatitis B Vaccines Tier 1, Tier 2, and Tier 3
4 Hepatitis B Vaccines Market by Type
- 4.1 Hepatitis B Vaccines Type Introduction
- 4.1.1 Yeast Derived
- 4.1.2 CHO Derived
- 4.2 Global Hepatitis B Vaccines Sales by Type
- 4.2.1 Global Hepatitis B Vaccines Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hepatitis B Vaccines Sales by Type (2021-2032)
- 4.2.3 Global Hepatitis B Vaccines Sales Market Share by Type (2021-2032)
- 4.3 Global Hepatitis B Vaccines Revenue by Type
- 4.3.1 Global Hepatitis B Vaccines Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hepatitis B Vaccines Revenue by Type (2021-2032)
- 4.3.3 Global Hepatitis B Vaccines Revenue Market Share by Type (2021-2032)
5 Hepatitis B Vaccines Market by Application
- 5.1 Hepatitis B Vaccines Application Introduction
- 5.1.1 Children
- 5.1.2 Adult
- 5.2 Global Hepatitis B Vaccines Sales by Application
- 5.2.1 Global Hepatitis B Vaccines Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hepatitis B Vaccines Sales by Application (2021-2032)
- 5.2.3 Global Hepatitis B Vaccines Sales Market Share by Application (2021-2032)
- 5.3 Global Hepatitis B Vaccines Revenue by Application
- 5.3.1 Global Hepatitis B Vaccines Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hepatitis B Vaccines Revenue by Application (2021-2032)
- 5.3.3 Global Hepatitis B Vaccines Revenue Market Share by Application (2021-2032)
6 Global Hepatitis B Vaccines Sales by Region
- 6.1 Global Hepatitis B Vaccines Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hepatitis B Vaccines Sales by Region (2021-2032)
- 6.2.1 Global Hepatitis B Vaccines Sales by Region (2021-2026)
- 6.2.2 Global Hepatitis B Vaccines Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hepatitis B Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hepatitis B Vaccines Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hepatitis B Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hepatitis B Vaccines Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hepatitis B Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hepatitis B Vaccines Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hepatitis B Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hepatitis B Vaccines Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hepatitis B Vaccines Revenue by Region
- 7.1 Global Hepatitis B Vaccines Revenue by Region
- 7.1.1 Global Hepatitis B Vaccines Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hepatitis B Vaccines Revenue by Region (2021-2026)
- 7.1.3 Global Hepatitis B Vaccines Revenue by Region (2027-2032)
- 7.1.4 Global Hepatitis B Vaccines Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hepatitis B Vaccines Revenue (2021-2032)
- 7.2.2 North America Hepatitis B Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hepatitis B Vaccines Revenue (2021-2032)
- 7.3.2 Europe Hepatitis B Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hepatitis B Vaccines Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hepatitis B Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hepatitis B Vaccines Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hepatitis B Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GSK Hepatitis B Vaccines Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 NCPC
- 8.2.1 NCPC Company Information
- 8.2.2 NCPC Business Overview
- 8.2.3 NCPC Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 NCPC Hepatitis B Vaccines Product Portfolio
- 8.2.5 NCPC Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Hepatitis B Vaccines Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Bio Kangtai
- 8.4.1 Bio Kangtai Company Information
- 8.4.2 Bio Kangtai Business Overview
- 8.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Bio Kangtai Hepatitis B Vaccines Product Portfolio
- 8.4.5 Bio Kangtai Recent Developments
- 8.5 Dynavax
- 8.5.1 Dynavax Company Information
- 8.5.2 Dynavax Business Overview
- 8.5.3 Dynavax Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Dynavax Hepatitis B Vaccines Product Portfolio
- 8.5.5 Dynavax Recent Developments
- 8.6 Hissen
- 8.6.1 Hissen Company Information
- 8.6.2 Hissen Business Overview
- 8.6.3 Hissen Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Hissen Hepatitis B Vaccines Product Portfolio
- 8.6.5 Hissen Recent Developments
- 8.7 KM Biologics
- 8.7.1 KM Biologics Company Information
- 8.7.2 KM Biologics Business Overview
- 8.7.3 KM Biologics Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 KM Biologics Hepatitis B Vaccines Product Portfolio
- 8.7.5 KM Biologics Recent Developments
- 8.8 LG Life Sciences
- 8.8.1 LG Life Sciences Company Information
- 8.8.2 LG Life Sciences Business Overview
- 8.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 LG Life Sciences Hepatitis B Vaccines Product Portfolio
- 8.8.5 LG Life Sciences Recent Developments
- 8.9 Serum Institute
- 8.9.1 Serum Institute Company Information
- 8.9.2 Serum Institute Business Overview
- 8.9.3 Serum Institute Hepatitis B Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Serum Institute Hepatitis B Vaccines Product Portfolio
- 8.9.5 Serum Institute Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hepatitis B Vaccines Value Chain Analysis
- 9.1.1 Hepatitis B Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hepatitis B Vaccines Production Mode & Process
- 9.2 Hepatitis B Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hepatitis B Vaccines Distributors
- 9.2.3 Hepatitis B Vaccines Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst